Genpharm is proud to announce that it has entered into an agreement with Orchard Therapeutics for the commercialization and  to facilitate access to treatment with Libmeldy in European-based qualified treatment centres for eligible patients living in the Middle East.

Karim Smaira Genpharm’s CEO, “Given the severity of MLD and the lack of any other approved treatment options, we are honoured to partner with Orchard Therapeutics to support eligible young MLD patients and their families in getting to Europe for treatment with such an innovative and promising therapy as Libmeldy.”

About Orchard Therapeutics
Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist. For more information, visit https://www.orchard-tx.com.